Real-World Treatment Adherence and Persistence with C5 Inhibitor Therapy Versus Satralizumab in Patients with Neuromyelitis Optica Spectrum Disorder in Japan

Key Points

• This research aims to compare treatment adherence and persistence between C5 inhibitor therapy and satralizumab in patients with neuromyelitis optica spectrum disorder (NMOSD) in Japan.
• Real-world study design conducted in Japan
• Comparison of treatment adherence and persistence between C5 inhibitors and satralizumab
• Focus on patients diagnosed with neuromyelitis optica spectrum disorder
• Patients receiving C5 inhibitors showed higher treatment adherence compared to those on satralizumab.
• Persistence with C5 inhibitor therapy was also significantly greater than with satralizumab.
• Further research is needed to investigate long-term adherence and persistence.